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March 16, 2010:1163–7hereby the global hemodynamic burden imposed on the LV. In
his context, the calculation of Zva allows the detection of patients
aving an abnormally high hemodynamic load occulted by para-
oxical low flow and associated pseudonormalization of gradient
nd blood pressure. The Zva also provides more insight into the
athophysiology of symptomatic patients with the combination of
ypertension and less-than-severe AS. In the discussion, we have
onetheless emphasized that in this situation future studies are
ecessary to determine how these findings can be translated into
linical practice to improve the diagnosis, treatment, and prognosis.
In time, the development of LV dysfunction and the occurrence
f adverse events (including symptoms, atrial fibrillation, heart
ailure, cardiovascular deaths, and so on) should logically be related
o the global hemodynamic burden imposed by AS and/or hyper-
ension on the LV and upstream cardiac chambers. We thus
elieve that the first essential step in the evaluation of these
atients is to estimate the global hemodynamic load to determine
hether the patient is at risk for poor outcome. The Zva is
articularly useful in this regard as it provides a simple and
oninvasive parameter for estimating the global load and predict-
ng outcomes. The second step is then to dissect the respective
ontributions of AS and hypertension to the increased global
urden by examining the indexes of the valvular and arterial loads,
espectively. To this effect, the clinician should be cautious about
he use of transvalvular gradient and blood pressure for clinical
ecision making because these indexes may be pseudonormalized.
hey should preferably use indexes that are less flow dependent,
uch as the aortic valve area or energy loss index for assessment of
alvular load and arterial compliance and vascular resistance for the
ssessment of arterial load.
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-Type Natriuretic Peptide
ssay to Diagnose Significant
ardiovascular Disease
n Children
e read with interest the paper of Law et al. (1) regarding the
ccuracy of B-type natriuretic peptide (BNP) to diagnose signifi-
ant cardiovascular disease in children. In their prospective study
he authors enrolled 100 children (including 42 neonates) present-
ng with signs and symptoms that might be attributable to
ardiovascular abnormalities. Their results clearly showed how the
se of BNP was helpful in discriminating children with structural
r functional cardiovascular diseases. They indicated how, up to 7
ays of life, the cutoff of 170 ng/l had a positive predictive value of
1% in ruling out cardiac disease, whereas in older children a BNP
alue of 41 ng/l had a positive predictive value of 77%. Plasma
NP was measured with a point-of-care testing method (Triage
NP, Biosite, Inc., San Diego, California).
On the basis of our experience, we appreciate and encourage the
dea to use BNP in the integrated approach of newborns and
hildren with suspected cardiovascular diseases. However, we
elieve that the use of 2 different cutoffs—1 for newborns up to 7
ays and the other for all the other children—might represent an
versimplification. We assessed the reference interval limits of
NP assay in newborns and infants in a wide population of healthy
ubjects, with the same triage BNP method, performed on the fully
utomated Access platform (Triage BNP reagents, Access Immu-
oassay Systems, REF 98200, Beckman Coulter, Inc., Fullerton,
alifornia) (2). Plasma BNP was measured in 190 apparently
ealthy newborns and infants throughout the first month of
xtra-uterine life, as well as in 184 healthy infants, with ages
anging from 1 month to 12 years. The BNP showed the highest
evels in the first 2 days of life (median 229.0 ng/l, range 41 to 866
g/l, 97.5th percentile, 745 ng/l, n 91) with a progressive decline
n the next days (BNP values from 49 to 190 h of life: median
10.0 ng/l, range 10 to 739 ng/l, 97.5th percentile, 480 ng/l, n 
9). Moreover, due to the great variability of circulating levels, the
iagnostic accuracy of BNP assay might be significantly lower in
he first days of life, especially if incorrect cutoff values are taken
nto account. Considering the 97.5th percentile as a possible
pper limit for the reference interval, we propose 3 different
ecision levels for the diagnosis of cardiovascular disease in
hildren: 1 for the first 2 days of life (i.e., 750 ng/l), 1 from the
hird to seventh day (i.e., 480 ng/l), and the other from 2 weeks
o 10 years (i.e., 45 ng/l).
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eply
antinotti et al. (1) propose adopting the 97.5th percentile value as
cutoff for B-type natriuretic peptide (BNP) levels based on the
esults of their excellent study in presumed healthy newborns.
sing cutoff values based on the distribution from a healthy
opulation is fundamentally different from the derivation of cutoffs
rom a study of disease and nondisease subjects. The Better Not
out Children! Study (2) was a field test of sick infants and
hildren whose presentation could be caused by cardiovascular
isease. The results are intended to be applied to similar patients
n clinical practice. In the presence of trial data, use of 97.5th-
ercentile cutoffs fails to take advantage of valuable information
rom individuals who suffer from the disease but have test values
hat fall within 2 SDs above the mean of healthy subjects. For
xample, with the cutoffs proposed by Cantinotti et al. (1), the
ensitivity was only 43% and 49% for the 0- to 2-day-old and 3- to
-day-old groups, respectively, and 100% specific for both groups
f subjects from our study. Thus, the result of using this method-
logy, choosing the 97.5th percentile cutoff and applying it to a
ifferent group of subjects, would have increased test specificity
nd sacrificed sensitivity. We found in our study that, between
irth and 7 days of age, a cutoff of 170 pg/ml was sufficient to
iagnose significant cardiovascular disease with excellent sensitivity
93%) and reasonable specificity (73%). We believe that optimi-
ation of the sensitivity is clinically important in the identification
3f significant cardiovascular disease in the sick infant by the
rontline physician.
A second point relates to the dramatic fall in BNP values during
he first week of life. Multiple works (1,3) have shown that BNP
alues decrease dramatically in the first week of life and vary widely
ithin each age group even when separated by a single day. Thus,
t would be preferable to determine daily cutoffs during this critical
nd rapidly changing early phase of life. Unfortunately, our study
as neither intended nor powered to address this important
uestion.
Properly conducted prospective trials in pediatric cardiology are
acking. Instead of extrapolating data from normative values,
etrospective studies, or adult trials, prospective trials in children
hould be conducted. Ours was one of the early trials and hopefully
ot the last to assess BNP in children. Future studies should
ddress: 1) neonatal cutoffs by expanding the pool and sample size
f sick neonates; and 2) whether using BNP actually enhances the
iagnostic process and the outcome of the patient. There is much
romise in the use of BNP to diagnose significant cardiovascular
isease in children. But because of the tremendous physiological
nd disease heterogeneity in children, that test cutoff is truly a
oving target, and much work still has to be done.
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